We are live on
!
Find out more
AQR Capital Management Portfolio holdings
AUM
$218B
1-Year Est. Return
29.41%
This Fund
S&P 500
This Quarter
Est. Return
+8.82%
1 Year Est. Return
+29.41%
3 Year Est. Return
+92.15%
5 Year Est. Return
+116.61%
10 Year Est. Return
+435.72%
AUM
$156B
AUM Growth
+$35.1B
(+29%)
Cap. Flow
+$26.6B
Cap. Flow
% of AUM
17.03%
Top 10 Holdings %
Top 10 Hldgs %
12%
Holding
3,631
New
339
Increased
2,078
Reduced
973
Closed
175
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$854M |
| 2 |
Walmart Inc
WMT
|
+$758M |
| 3 |
NVIDIA
NVDA
|
+$464M |
| 4 |
PepsiCo
PEP
|
+$462M |
| 5 |
FedEx
FDX
|
+$396M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Fortinet
FTNT
|
+$332M |
| 2 |
Arista Networks
ANET
|
+$319M |
| 3 |
DoorDash
DASH
|
+$252M |
| 4 |
Monster Beverage
MNST
|
+$227M |
| 5 |
Costco
COST
|
+$216M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 24.74% |
| 2 | Financials | 14.8% |
| 3 | Industrials | 12.12% |
| 4 | Healthcare | 11.96% |
| 5 | Consumer Discretionary | 11.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3376
Lifecore Biomedical
LFCR
$183M
| $92.7K | ﹤0.01% |
12,597
+1,146
| +10% | +$8.67K |
|
3377
Capricor Therapeutics
CAPR
$228M
| $89.1K | ﹤0.01% |
+12,361
| New | +$91K |
|
3378
Omeros
OMER
$984M
| $87.4K | ﹤0.01% |
21,306
+7,444
| +54% | +$29.5K |
|
3379
Foghorn Therapeutics
FHTX
$391M
| $86.9K | ﹤0.01% |
17,778
-80
| -0.4% | -$424 |
|
|
UHG
3380
DELISTED
United Homes Group
UHG
| $84.7K | ﹤0.01% |
20,500
-66,736
| -77% | -$262K |
|
|
HURA
3381
TuHURA Biosciences
HURA
$146M
| $84.5K | ﹤0.01% |
+34,065
| New | +$89.7K |
|
|
WOW
3382
DELISTED
WideOpenWest
WOW
| $84.1K | ﹤0.01% |
+16,304
| New | +$73.1K |
|
|
PHLT
3383
DELISTED
Performant Healthcare Inc
PHLT
| $84.1K | ﹤0.01% |
+10,875
| New | +$69.2K |
|
|
EEX
3384
DELISTED
Emerald Holding
EEX
| $83.8K | ﹤0.01% |
16,472
+1,119
| +7% | +$5.65K |
|
3385
Ispire Technology
ISPR
$99.9M
| $82.8K | ﹤0.01% |
32,363
+17,994
| +125% | +$52.3K |
|
3386
Lucid Diagnostics
LUCD
$183M
| $81.5K | ﹤0.01% |
+80,696
| New | +$88.1K |
|
3387
Kyverna Therapeutics
KYTX
$488M
| $81.3K | ﹤0.01% |
13,542
-86,616
| -86% | -$346K |
|
3388
Entrada Therapeutics
TRDA
$274M
| $81.1K | ﹤0.01% |
13,991
-21,629
| -61% | -$127K |
|
3389
Paysign
PAYS
$713M
| $79.3K | ﹤0.01% |
12,605
+543
| +5% | +$3.47K |
|
|
SBC
3390
SBC Medical Group
SBC
$328M
| $78.9K | ﹤0.01% |
+18,174
| New | +$82K |
|
3391
Atomera
ATOM
$217M
| $78.4K | ﹤0.01% |
+17,735
| New | +$72.8K |
|
3392
Wave Life Sciences
WVE
$993M
| $78.3K | ﹤0.01% |
+10,698
| New | +$86.6K |
|
|
SCPH
3393
DELISTED
scPharmaceuticals
SCPH
| $76.9K | ﹤0.01% |
13,567
+3,076
| +29% | +$15.8K |
|
3394
Crexendo
CXDO
$214M
| $76.8K | ﹤0.01% |
+11,822
| New | +$73.3K |
|
3395
Ranpak Holdings
PACK
$461M
| $76.6K | ﹤0.01% |
13,637
+2,109
| +18% | +$9.23K |
|
3396
Blue Ridge Bankshares
BRBS
$335M
| $75.3K | ﹤0.01% |
+17,793
| New | +$68.9K |
|
3397
Recursion Pharmaceuticals
RXRX
$1.8B
| $72.8K | ﹤0.01% |
14,910
+1,010
| +7% | +$5.3K |
|
|
SNCR
3398
DELISTED
Synchronoss Technologies
SNCR
| $69.5K | ﹤0.01% |
+11,435
| New | +$77.8K |
|
3399
Chegg
CHGG
$92.8M
| $69.4K | ﹤0.01% |
45,964
-1,782,088
| -97% | -$2.5M |
|
3400
Arbutus Biopharma
ABUS
$923M
| $69.2K | ﹤0.01% |
15,233
-22,469
| -60% | -$82.5K |
|
Similar funds
VGA
AQR Capital Management's Q3 2025 Portfolio in Review
As of Q3 2025, AQR Capital Management held 3,631 positions worth $156B, up 29% from $121B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
AQR Capital Management deployed $26.6B of net new capital in Q3 2025, opening 339 new positions and adding to 2,078 existing holdings. Its largest new stake was Rubrik: 1,189,403 shares worth $97.8M.
By sector, the portfolio is most concentrated in Technology at 25% of assets, down from 25% a quarter earlier, followed by Financials and Industrials.
On the sell side, the largest reduction was Fortinet, an estimated $332M trimmed.
- AQR Capital Management's largest Q3 2025 buy was Rubrik: 1,189,403 shares worth $97.8M.
- AQR Capital Management added most to Microsoft in Q3 2025, an estimated $854M increase.
- AQR Capital Management's biggest Q3 2025 reduction was Fortinet, cutting an estimated $332M.
- AQR Capital Management fully exited Qfin Holdings in Q3 2025, selling an estimated $114M.
- AQR Capital Management's ten largest holdings make up 12% of its $156B portfolio in Q3 2025.
- AQR Capital Management opened 339 new positions and closed 175 in Q3 2025.
- AQR Capital Management's portfolio value rose 29% quarter-over-quarter to $156B.
Based on AQR Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.